The companies in July said Mylan would buy Abbott's drug portfolio in developed overseas markets, in a $5.3 billion deal that would allow Mylan to benefit from a lower tax rate by organizing the new company in the Netherlands.
Amid the stampede of Western multinationals pushing to expand in China and India, a few are way out ahead of the pack. Take Abbott Laboratories (No. 136 on the Fortune 500), for instance. The Illinois-based maker of nutritional products and medical ...
Back in 2012 Abbott Laboratories found itself subject to criminal and civil charges by the US Justice Department. This involved the illegal promotion of the Abbott's drug Depakote; for uses not approved by the US Food and Drug Administration (FDA).
Abbott Laboratories also has a broad and balanced portfolio, with Medical Devices representing 27% of sales, Established Pharmaceuticals representing 16% of sales, Diagnostics representing 23% of sales, and Nutrition representing 34% of sales.
Looking at the universe of stocks we cover at Dividend Channel, on 4/13/15, AbbVie Inc. (NYSE: ABBV), Abbott Laboratories (NYSE: ABT), and Pennymac Mortgage Investment Trust (NYSE: PMT) will all trade ex-dividend for their respective upcoming ...
Abbott Laboratories (NYSE:ABT) plans to offer almost 32% of its stake in Mylan NV (NASDAQ:MYL), only after a week after Mylan bought a drug portfolio from Abbott in exchange for stock worth $5.3 billion.
[PRNewswire] Abbott Laboratories (NYSE:ABT)(TREND ANALYSIS), About three years ago, Betty Vaughn of Golden Valley, Minn., started to feel light-headed, fatigued and out of breath when she walked up and down the stairs.
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of ��240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.